Features of cytomegalovirus DNAemia and virus‐specific T‐cell responses in allogeneic hematopoietic stem‐cell transplant recipients during prophylaxis with letermovir
Transplant Infectious Disease · 2023
DOI: 10.1111/tid.14021 ↗Kurz gefasst
Fachartikel in der Zeitschrift Transplant Infectious Disease, 2023. Verfasst von Estela Giménez und 12 weiteren Autor:innen. Beteiligte Einrichtung: Microbiology Service, Hospital Clínico Universitario, INCLIVA Health Research Institute, Valencia, Spain. Hauptthemen laut MEDLINE: Cytomegalovirus Infections, Hematopoietic Stem Cell Transplantation. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 28 Literaturangaben. Gefördert von: Merck, Sharp & Dohme (MSD), Carlos III Health Institute, Instituto de Salud Carlos III.
Abstract (Originalsprache)
Background
There is scarce information on the natural kinetics of cytomegalovirus (CMV) DNAemia and dynamics of CMV‐specific T‐cell reconstitution in allogeneic hematopoietic transplant recipients (allo‐HSCT) undergoing letermovir (LMV) prophylaxis.
Methods
Twelve adult CMV‐seropositive high‐risk recipients (median age, 53 years; 9 males/3 females) undergoing LMV prophylaxis and 13 non‐LMV allo‐HSCT controls (median age, 58 years; 7 males/6 females) were included. CMV DNAemia in plasma was monitored by real‐time polymerase chain reaction. Preemptive antiviral therapy (PET) was administered upon detection of ≥1500 IU/ml. CMV‐specific interferon‐gamma (IFN‐γ)‐producing CD8 + and CD4 + T cells were enumerated by flow cytometry around days +30, +60, and +90 after allo‐HSCT. Ex vivo experiments assessing of the potential effect of LMV on CMV‐specific T‐cell expansion in a single CMV‐seropositive donor were also conducted.
Results
Five LMV patients (41.6%) developed CMV DNAemia that cleared spontaneously. Four patients (33.3%) developed CMV DNAemia after LMV cessation, of which two required PET. Nine non‐LMV patients (69.2%) developed CMV DNAemia (five required PET). The percentage of LMV and non‐LMV patients exhibiting detectable CMV‐specific T‐cell responses was comparable (7/10 vs. 10/13; p = .71). Nevertheless, median CMV‐specific CD4 + and CD8 + T‐cell counts were lower in LMV patients by days +60 ( p = .006 and .02, respectively) and +90 ( p = .08 and .02). Ex vivo, CMV‐specific CD8 + T cells expanded to the same level either in the presence (19.8%) or in the absence of LMV (20.6%).
Conclusions
In our series, episodes of CMV DNAemia in LMV patients cleared spontaneously. A diminished degree of CMV‐specific T‐cell reconstitution in LMV patients compared to non‐LMV patients was observed. image
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Microbiology Service, Hospital Clínico Universitario, INCLIVA Health Research Institute, Valencia, Spain.
- Centro de Investigación Biomédica en Red de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, Madrid, Spain.
- Hematology Service, Hospital Universitario y Politécnico "La Fe", Valencia, Spain.
- Hematology Service, Hospital Clínico Universitario, INCLIVA Health Research Institute, Valencia, Spain.
- Department of Medicine, School of Medicine, University of Valencia, Valencia, Spain.
- Department of Microbiology, School of Medicine, University of Valencia, Valencia, Spain.
ORCID-Profile: Cristobal Aguilar, José Luis Piñana, David Navarro
Förderung
- Merck, Sharp & Dohme (MSD)
- Carlos III Health Institute
- Instituto de Salud Carlos III
Zitieren
APA
Giménez, E., Guerreiro, M., Torres, I., Aguilar, C., Albert, E., Hernández-Boluda, J. C., Hernani, R., Pérez, A., Amat, P., Piñana, J. L., Montoro, J., Solano, C., & Navarro, D. (2023). Features of cytomegalovirus DNAemia and virus‐specific T‐cell responses in allogeneic hematopoietic stem‐cell transplant recipients during prophylaxis with letermovir. Transplant Infectious Disease. https://doi.org/10.1111/tid.14021
Vancouver
Giménez E, Guerreiro M, Torres I, Aguilar C, Albert E, Hernández-Boluda JC, et al. Features of cytomegalovirus DNAemia and virus‐specific T‐cell responses in allogeneic hematopoietic stem‐cell transplant recipients during prophylaxis with letermovir. Transplant Infectious Disease. 2023. doi:10.1111/tid.14021
BibTeX
@article{Gimnez2023,
author = {Giménez, Estela and Guerreiro, Manuel and Torres, Ignacio and Aguilar, Cristobal and Albert, Eliseo and Hernández-Boluda, Juan Carlos and Hernani, Rafael and Pérez, Ariadna and Amat, Paula and Piñana, José Luis and Montoro, Juan and Solano, Carlos and Navarro, David},
title = {Features of cytomegalovirus DNAemia and virus‐specific T‐cell responses in allogeneic hematopoietic stem‐cell transplant recipients during prophylaxis with letermovir},
journal = {Transplant Infectious Disease},
year = {2023},
doi = {10.1111/tid.14021}
}
EUVIMED